Why is Brawn Biotech falling/rising?

As of 11-Jul, Brawn Biotech Ltd's stock price is currently at 19.17, reflecting an increase of 0.91 or 4.98%. The stock has shown a positive trend recently, gaining 8.92% over the last two days and outperforming its sector by 6.03% today. However, despite this short-term gain, the stock has underperformed in the longer term, with a 1-year return of -19.28% and a year-to-date decline of -10.04%. The company faces significant challenges, including operating losses and a weak long-term fundamental strength, as evidenced by a net sales growth rate of -22.97% and an operating profit decline of 209.72% over the past five years. Additionally, the stock is considered risky due to negative EBITDA and poor ability to service its debt.
In the broader market context, while Brawn Biotech's recent performance has been positive, it has still lagged behind the benchmark, with a 1-week return of -4.10% compared to the Sensex's -1.12%. The stock's liquidity appears adequate for trading, but a notable decline in delivery volume by 59.72% against the 5-day average suggests a decrease in investor participation. Overall, while the stock has experienced a short-term rise, the underlying financial difficulties and long-term performance issues indicate a precarious position in the market.